Pharmaceuticals

Curosurf (Poractant Alfa) Market 2026–2030: Emerging Trends and Forecast Opportunities

March 5, 2026March 5, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the curosurf (poractant alfa) market from 2026–2035 with trusted insights from The Business Research Company

How much is the Curosurf (Poractant Alfa) Market valued at in 2026, and what valuation is forecast for 2030?

Historically, growth stemmed from the frequent occurrences of premature births, the demonstrated effectiveness in treating respiratory distress syndrome, the widespread implementation of Neonatal Intensive Care Units, clinical recommendations favoring surfactant treatment, and a decrease in infant death rates.

The projected growth in the forecast period is attributable to a global rise in premature birth rates, the expansion of nicu infrastructure, enhanced access to neonatal care, increasing awareness regarding early rds intervention, and continued clinical validation. Prominent trends anticipated during the forecast timeframe include a surge in use within neonatal intensive care, a growing adoption of synthetic surfactants, an increasing focus on preterm birth management, the standardization of rds treatment protocols, and the expansion of hospital-based neonatal therapies.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19893&type=smp

What Drivers Are Influencing The Growth Of The Curosurf (Poractant Alfa) Market?

The rise in respiratory conditions is anticipated to fuel the expansion of the curosurf (poractant alfa) market moving forward. These common disorders impact the lungs and breathing, encompassing conditions such as asthma, COPD, and lung cancer, resulting in breathing difficulties and reduced pulmonary function. The increasing incidence of respiratory illnesses is attributed to rising air pollution, which worsens conditions like asthma, and a growing elderly population, contributing to a higher frequency of age-related diseases such as COPD. Poractant alfa is utilized to address neonatal respiratory distress syndrome by enhancing lung function and facilitating respiration in premature infants through an endotracheal tube. For example, in December 2023, the National Library of Medicine, a US-based medical library, stated that the worldwide number of chronic obstructive pulmonary disease (COPD) cases among individuals aged 25 and above is projected to increase by 23% by 2050, reaching nearly 600 million. Consequently, the escalating prevalence of respiratory disorders is propelling the growth of the curosurf (poractant alfa) market. The increasing frequency of premature births is projected to drive the growth of the Curosurf (poractant alfa) market in the coming years. Premature births are defined as babies born prior to 37 weeks of gestation, whereas a full-term pregnancy typically lasts around 40 weeks. The increase in premature births is linked to factors such as older maternal age and a greater reliance on assisted reproductive technologies, which often lead to multiple pregnancies. Poractant alfa is employed to treat respiratory distress syndrome in premature infants by lowering lung surface tension, helping the lungs remain open, and improving oxygen exchange. As an illustration, in July 2025, the Office for National Statistics, a UK-based government department, reported that England and Wales experienced 594,677 live births in 2024, representing an increase of 3,605 (0.6%) from the 591,072 births recorded in 2023. Thus, the growing prevalence of premature births is contributing to the expansion of the Curosurf (poractant alfa) market.

How Is The Curosurf (Poractant Alfa) Market Organized Into Various Segments?

The curosurf (poractant alfa) market covered in this report is segmented –

1) By Type: Natural Poractant Alfa, Synthetic Poractant Alfa

2) By Sales Channel: Direct Sales, Distribution Channels, Online Marketplace

3) By Application: Pulmonary Edema, Respiratory Distress Syndrome, Other Respiratory Disorders

4) By End User: Hospitals, Clinics, Ambulance Services

How Are Emerging Trends Affecting The Progression Of The Curosurf (Poractant Alfa) Market?

Major companies engaged in the curosurf (poractant alfa) market are concentrating their efforts on devising advanced solutions, such as novel inhaled gene therapy, to meet critical unmet needs in various respiratory disorders. This innovative inhaled gene therapy involves a sophisticated technique where therapeutic genes are directly delivered to the lungs via inhalation, typically through the use of aerosolized particles or nanoparticles. For instance, in November 2024, AlveoGene, a UK-based company specializing in gene therapy development, secured Rare Pediatric Disease Designation (RPDD) from the FDA for AVG-002. This particular therapy is a novel inhaled gene therapy aimed at addressing lethal neonatal surfactant protein B (SP-B) deficiency, a severe genetic condition that results in respiratory failure in infants. SP-B deficiency, which stems from mutations in the SFTPB gene, currently has limited therapeutic options, primarily depending on lung transplantation. AVG-002 utilizes AlveoGene’s InGenuity platform to introduce a functional SP-B gene directly into the lungs, showing promising early results in preclinical studies.

Who Are The Core Companies Influencing Trends In The Curosurf (Poractant Alfa) Market?

Major companies operating in the curosurf (poractant alfa) market are Chiesi Farmaceutici S.p.A

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/curosurf-poractant-alfa-global-market-report-

Which Regions Are Projected To Dominate The Curosurf (Poractant Alfa) Market In The Coming Years?

North America was the largest region in the curosurf (poractant alfa) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the curosurf (poractant alfa) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Curosurf (Poractant Alfa) Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19893&type=smp

Browse Through More Reports Similar to the Global Curosurf (Poractant Alfa) Market 2026, By The Business Research Company

Alfalfa Market Report 2026

https://www.thebusinessresearchcompany.com/report/alfalfa-global-market-report

Compound Camphor Ointment Market Report 2026

https://www.thebusinessresearchcompany.com/report/compound-camphor-ointment-global-market-report

Pharmaceutical Pellets Market Report 2026

https://www.thebusinessresearchcompany.com/report/pharmaceutical-pellets-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795